CD40 ligand as a potential biomarker for atherosclerotic instability

Neurological Research

Volumn 35, Issue 7, 2013, Pages 693-700

  Wang, Jing Hua ^a   Zhang, Yong Wei ^b   Zhang, Ping ^b   Deng, Ben Qiang ^b   Ding, Suju ^b   Wang, Zhong Kui ^c   Wu, Tao ^b   Wang, Jian ^d  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c CHINESE PLA GENERAL HOSPITAL   (China)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Atherosclerosis; Biomarker; C reactive protein; CD40 ligand; Stroke

Indexed keywords

C REACTIVE PROTEIN; CD40 LIGAND; BIOLOGICAL MARKER;

ADULT; AGED; ARTERY EMBOLISM; ARTERY OCCLUSION; ARTICLE; ATHEROSCLEROTIC PLAQUE; BARTHEL INDEX; BRAIN ATHEROSCLEROSIS; BRAIN INFARCTION; CAROTID ARTERY OBSTRUCTION; COMPARATIVE STUDY; CONTROLLED STUDY; DISABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MAJOR CLINICAL STUDY; MALE; MINIMAL BRAIN DYSFUNCTION; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS; BLOOD; CEREBRAL INFARCTION; INTRACRANIAL ARTERIOSCLEROSIS; MIDDLE AGED; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CD40 LIGAND; CEREBRAL INFARCTION; FEMALE; HUMANS; INTRACRANIAL ARTERIOSCLEROSIS; MALE; MIDDLE AGED;

EID: 84882679128     PISSN: 01616412     EISSN: 17431328     Source Type: Journal    
DOI: 10.1179/1743132813Y.0000000190     Document Type: Article

References (29)

1. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med. 1999;340:115-26.
2. Hassan GS, Merhi Y, Mourad W. CD40 ligand: a neoinflammatory molecule in vascular diseases. Immunobiology. 2012;217:521-32.
3. Schönbeck U, Libby P. CD40 signaling and plaque instability. Circ Res. 2001;89:1092-103.
4. Mach F, Schonbeck U, Sukhova GK, Bourcier T, Bonnefoy JY, Pober JS, et al. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci USA. 1997;94:1931-6.
5. Hansson GK, Robertson AK, Soderberg-Naucler C. Inflammation and atherosclerosis. Annu Rev Pathol. 2006;1:297-329.
6. Mach F, Schonbeck U, Sukhova GK, Atkinson E, Lippy P. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature. 1998;394:200-3.
7. Lutgens E, Gorelik L, Daemen MJ, de Muinck ED, Grewal IS, Koteliansky VE et al. Requirement for CD154 in the progression of atherosclerosis. Nat Med. 1999;5:1313-6.
8. Schönbeck U, Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci. 2001;58:4-43.
9. Andre P, Nannizzi-Alaimo L, Prasad SK, Phillips DR. Plateletderived CD40L: the switch-hitting player of cardiovascular disease. Circulation. 2002;106:896-9.
10. Linden MD, Furman MI, Frelinger AL III, Fox ML, Barnard MR, Li Y, et al. Indices of platelet activation and the stability of coronary artery disease. J Thromb Haemost. 2007;5:761-5.
11. Lobbes MB, Lutgens E, Heeneman S, Cleutjens KB, Kooi ME, van Engelshoven JM, et al. Is there more than C-reactive protein and fibrinogen? The prognostic value of soluble CD40 ligand, interleukin-6 and oxidized low-density lipoprotein with respect to coronary and cerebral vascular disease. Atherosclerosis. 2006;187:18-25.
12. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Jr, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-207.
13. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836-43.
14. Di Napoli M, Schwaninger M, Cappelli R, Ceccarelli E, Di Gianfilippo G, Donati C, et al. Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: a statement for health care professionals from the CRP Pooling Project members. Stroke. 2005;36:1316-29.
15. Garlichs CD, Kozina S, Fateh-Moghadam S, Handschu R, Tomandl B, Stumpf C, et al. Upregulation of CD40-CD40 ligand (CD154) in patients with acute cerebral ischemia. Stroke. 2003;34:1412-8.
16. Wang J, Wang Z, Wu T, Deng B, Ding S, Chen H, et al. The roles of CD40-CD40L in carotid atherosclerotic plaque stability and their correlation with matrix metalloproteinase 9. Chin J Neurol. 2009;42:390-5.
17. Ay H, Furie KL, Singhal A, Smith WS, Sorensen AG, Koroshetz WJ, et al. An evidence-based causative classification system for acute ischemic stroke. Ann Neurol. 2005;58:688-97.
18. Tsai NW, Chang WN, Shaw CF, Jan CR, Chang HW, Huang CR, et al. Levels and value of platelet activation markers in different subtypes of acute non-cardio-embolic ischemic stroke. Thromb Res. 2009;124:213-8.
19. Antoniades C, Bakogiannis C, Tousoulis D, Antonopoulos AS, Stefanadis C. The CD40/CD40 ligand system: linking inflammation with atherothrombosis. J Am Coll Cardiol. 2009;54:669-77.
20. Bisoendial RJ, Boekholdt SM, Vergeer M, Stroes ES, Kastelein JJ. C-reactive protein is a mediator of cardiovascular disease. Eur Heart J. 2010;31:2087-91.
21. Kim SJ, Choe YH, Bang OY. Are stroke biomarkers seeing brain vessels in patients with ischemic stroke?: a C-reactive protein and homocysteine study. Stroke. 2011;42:1464-8.
22. Woodward M, Lowe GD, Campbell DJ, Colman S, Rumley A, Chalmers J, et al. Associations of inflammatory and hemostatic variables with the risk of recurrent stroke. Stroke. 2005;36(10):2143-7.
23. Mario DN, Francesca P, Vittorio B. C-reactive protein in ischemic stroke: an independent prognostic factor. Stroke. 2001;32:917-24.
24. Burke AP, Tracy RP, Kolodgie F, Malcom GT, Zieske A, Kutys R, et al. Elevated C-reactive protein values and atherosclerosis in sudden coronary death: association with different pathologies. Circulation. 2002;105:2019-23.
25. Burke AP, Farb A, Malcom GT, Liang YH, Smialek J, Virmani R. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med. 1997;336:1276-82.
26. Andre P, Prasad KS, Denis CV, He M, Papalia JM, Hynes RO, et al. CD40L stabilizes arterial thrombi by a beta3 integrin - dependent mechanism. Nat Med. 2002;8:247-52.
27. Schönbeck U, Varo N, Libby P, Buring J, Ridker PM. Soluble CD40L and cardiovascular risk in women. Circulation. 2001;104:2266-8.
28. Heeschen C, Dimmeler S, Hamm CW, van den Brand MJ, Boersma E, Zeiher AM, et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med. 2003;348:1104-11.
29. Wang J, Li J, Liu Q. Association between platelet activation and fibrinolysis in acute stroke patients. Neurosci Lett. 2005;384:305-9.